Full Press Release Details
Eupraxia Pharmaceuticals to Present
Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
Victoria, B.C. - June 5, 2024
- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology
company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need,
today announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at
the upcoming European Alliance of Associations for Rheumatology ("EULAR") European Congress of Rheumatology 2024 (the "Meeting").
The EULAR Meeting is being held in Vienna, Austria from June 12-15, 2024.
Presentation Details:
Programme No.: OP0274
Title: Efficacy of a Long-Acting Fluticasone Propionate Intra-Articular Injection (EP-104IAR) in Knee Osteoarthritis: Per-Protocol
Analysis of a Randomised, Double-Blind, Phase 2 Trial of EP-104IAR vs Vehicle Placebo (SPRINGBOARD)
Oral Abstract Presentation
Session Title: New Developments in Osteoarthritis
Session Date & Time: June 14, 2024, from 10:50 AM to 11:00 AM CEST
The presentation will also be available
on Eupraxia's website at:
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology
company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas
with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver
targeted, long-lasting activity with fewer side effects. DiffuSphere , a proprietary, polymer-based micro-sphere technology, is
designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic
(PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery
Eupraxia recently completed a Phase 2b
clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint
and three of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a
RESOLVE trial for treating eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations.
Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the
activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements
This news release includes forward-looking
statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information
can be identified by the use of words such as "plans", "is expected", "expects", "suggests",
"scheduled", "intends", "contemplates", "anticipates", "believes", "proposes",
"potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions,
events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.
Forward looking statements in this news release include statements regarding the details of the Company's presentations at the upcoming
EULAR Meeting; the Company's product candidates, including expected benefits to patients with respect to safety, efficacy, duration and
tolerability; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology
to impact the drug delivery process; and potential pipeline indications. Such statements and information are based on the current expectations
of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company
proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales;
the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and
the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying
these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed
in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors
and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating
history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it
licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to
its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's
technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly
and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited
uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates
at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other
safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the
Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not
be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any
therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect
the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the
Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties,
including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described
in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov).
Although Eupraxia has attempted to identify
important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements
and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended.
No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements
and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any
forward-looking statement or information, whether as a result of new information, future events or otherwise.
For investor and media inquiries, please contact:
Danielle Egan, Eupraxia Pharmaceuticals Inc.
Adam Peeler, on behalf of:
Eupraxia Pharmaceuticals Inc.
SOURCE Eupraxia Pharmaceuticals Inc.